ABOUT US

 

ProtExtent Biosolutions Pvt. Ltd. (PBPL) specializes in production of recombinant proteins. PBPL has developed a combination of efficient processes involved in expression and purification for achieving cost-effective production of recombinant proteins.

At PBPL, we have the expertise and proven track-record (core team’s combined experience of >30 years) in expression and purification of recombinant proteins using a variety of recombinant protein expression platforms.

As a flagship in-house R&D program, PBPL is developing a novel and versatile Virus Like Particle (VLP) based platform amenable to highly efficient bioconjugation (essentially in a ‘plug-n-display’ format) with different antigens of choice for improving their immunogenicity. The roadmap involving different business interests of PBPL is shown schematically in the figure below.





PBPL provides Contract Research Services to various requirements in process developments requirements involving optimization of expression, purification and scale-up of recombinant proteins.

PBPL conductsother aligned in-house R&D activities for producing recombinant industrial enzymes and cost-effective biotherapeutics .

FOUNDERS



Dr. Shalini Singh

Dr. Shalini Singh, has a PhD in Biochemistry from CSIR-CDRI, Lucknow, withpost-doctoral research experience in anti-mycobacterial drug discovery from NIH, MD, USA. She has extensive research expertise in protein purification, proteomic characterization, bioanalytical sciences and understanding of host-pathogen interactions. She aspires to contribute towards achieving affordable healthcare for all.

Dr. Vandana Singh

Dr. Vandana Singh, has a PhD in Applied Chemistry from IIT-BHU, Varanasi, with extensive research experience in nanomaterials and conducting-polymer based biosensors. She acquired postdoctoral research experience at Staten Serum Institute, Copenhagen, extensively on recombinant protein expression, purification, process development and cGMP scale-up. She has interests in developing cost-effective biotherapeutics.

Dr. Subhash Singh

Dr. Subhash Singh, has a PhD in Medical Parasitology from Pasteur Institute, Paris, with MSc (Molecular Biology, TIFR, Mumbai) and post-doctoral research experience from NIH, MD, USA, and University of Copenhagen, Denmark. His research experience (>25 years) spansinfectious diseases, host-parasite interactions, immunology, vaccine research, recombinant protein technology and biotherapeutics.